Swedbank AB Raises Stake in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Swedbank AB increased its stake in Vertex by 2.6% in Q4 to 260,743 shares (about $118.21 million), representing roughly 0.10% of the company.
• Q1 results beat expectations with adjusted EPS $4.47 versus $4.24 and revenue of $2.99 billion (up ~8%), the company reiterated 2026 guidance and analysts largely raised price targets — consensus rating is "Moderate Buy" with a $555.17 target.
• Insiders have sold a total of 81,853 shares valued at $38.48 million in the last 90 days while institutional investors own about 90.96% of the stock and corporate insiders hold only 0.20%, a dynamic that could weigh on near‑term sentiment.

Swedbank AB increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 2.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 260,743 shares of the pharmaceutical company's stock after acquiring an additional 6,647 shares during the period. Swedbank AB owned approximately 0.10% of Vertex Pharmaceuticals worth $118,210,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC increased its position in Vertex Pharmaceuticals by 15.0% during the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company's stock valued at $1,783,000 after buying an additional 579 shares in the last quarter. Gamco Investors INC. ET AL bought a new stake in Vertex Pharmaceuticals in the second quarter worth $228,000. NewEdge Advisors LLC boosted its holdings in Vertex Pharmaceuticals by 9.0% in the second quarter. NewEdge Advisors LLC now owns 11,929 shares of the pharmaceutical company's stock worth $5,311,000 after acquiring an additional 986 shares in the last quarter. ICW Investment Advisors LLC grew its stake in shares of Vertex Pharmaceuticals by 5.0% in the second quarter. ICW Investment Advisors LLC now owns 604 shares of the pharmaceutical company's stock worth $269,000 after acquiring an additional 29 shares during the last quarter. Finally, Diversify Advisory Services LLC increased its holdings in shares of Vertex Pharmaceuticals by 26.3% during the second quarter. Diversify Advisory Services LLC now owns 7,291 shares of the pharmaceutical company's stock valued at $3,246,000 after acquiring an additional 1,518 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.

Insider Buying and Selling

In other news, EVP Mark E. Bunnage sold 620 shares of the firm's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total value of $301,537.00. Following the transaction, the executive vice president directly owned 7,284 shares in the company, valued at $3,542,573.40. This trade represents a 7.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Sangeeta N. Bhatia sold 318 shares of Vertex Pharmaceuticals stock in a transaction on Monday, May 4th. The stock was sold at an average price of $423.73, for a total value of $134,746.14. Following the completion of the sale, the director directly owned 4,924 shares of the company's stock, valued at $2,086,446.52. The trade was a 6.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 81,853 shares of company stock valued at $38,479,135 in the last ninety days. Corporate insiders own 0.20% of the company's stock.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Germany reimbursement for CASGEVY secures payer access for eligible patients (age ≥12) with sickle cell disease and transfusion‑dependent beta thalassemia — a meaningful commercial milestone for a one‑time gene‑editing therapy. Business Wire: CASGEVY reimbursement
• Positive Sentiment: Q1 results: adjusted EPS beat estimates ($4.47 vs. $4.24) and revenue grew ~8% to $2.99B, driven by CF franchise and recently launched products — supports medium‑term revenue trajectory. Zacks: Q1 earnings beat
• Positive Sentiment: Industry recognition: National Kidney Foundation honored Vertex with a 2026 Kidney Biotech Innovation Award — incremental reputational/PR support for non‑CF pipeline work. Yahoo Finance: NKF award
• Neutral Sentiment: Company reiterated 2026 guidance (revenue roughly in line with consensus) — provides stability but limits upside surprise potential. Investor slide deck (Q1)
• Neutral Sentiment: Analysts reacted by trimming price targets while generally remaining constructive — many keep Buy/Outperform ratings but lowered near‑term upside. Benzinga: Analyst revisions after Q1
• Negative Sentiment: Insider selling reported (EVP Joy Liu sold ~1,104 shares; Director Sangeeta Bhatia sold 318 shares) under 10b5‑1 plans — routine but can pressure sentiment when clustered after earnings. InsiderTrades: insider selling
• Negative Sentiment: Market reaction was muted to negative after the quarter: some commentators say the update was “mixed” (beat on EPS but other reads left investors cautious), prompting near‑term profit‑taking. Yahoo: Is it too late to consider VRTX?
• Negative Sentiment: Debate over growth strategy: some analysts/commentators argue Vertex may need bolder M&A to diversify beyond CF and accelerate non‑CF pipeline commercialization — strategic risk that could temper valuation expansion. Seeking Alpha: Q1 review / M&A commentary
• Negative Sentiment: Small insider option grant reported (Michel Lagarde acquired ~$9K in options) — modest signal but immaterial to near‑term share moves. Benzinga: Michel Lagarde options

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Bank of America lifted their price target on Vertex Pharmaceuticals from $571.00 to $598.00 and gave the stock a "buy" rating in a research report on Tuesday, March 10th. Morgan Stanley raised their price objective on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the company an "overweight" rating in a research note on Tuesday. HC Wainwright lifted their target price on shares of Vertex Pharmaceuticals from $591.00 to $641.00 and gave the stock a "buy" rating in a report on Tuesday, March 10th. Barclays upped their target price on shares of Vertex Pharmaceuticals from $607.00 to $615.00 and gave the stock an "overweight" rating in a research note on Wednesday. Finally, Royal Bank Of Canada increased their price target on shares of Vertex Pharmaceuticals from $541.00 to $543.00 and gave the company an "outperform" rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $555.17.

Vertex Pharmaceuticals Stock Performance

VRTX opened at $427.65 on Thursday. The stock has a market capitalization of $108.78 billion, a P/E ratio of 25.36, a P/E/G ratio of 1.85 and a beta of 0.30. The company's 50-day simple moving average is $451.70 and its two-hundred day simple moving average is $449.73. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $507.92.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, topping analysts' consensus estimates of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The firm had revenue of $2.99 billion during the quarter, compared to analyst estimates of $2.99 billion. During the same period in the previous year, the business posted $4.06 earnings per share. The business's revenue for the quarter was up 8.3% on a year-over-year basis. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.81 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.